Skip to main content
MyDeficiencies

Insulin detemir

Long-Acting Insulin Analogue

Also sold as Levemir.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Insulin detemir has essentially no classical depletion machinery. It is a 51-amino-acid peptide analog of human insulin (with a C14 fatty-diacid side chain enabling reversible albumin binding) given only by subcutaneous injection. It is not metabolized by hepatic drug-metabolizing (CYP450) enzymes, does not induce or inhibit any CYP450 enzyme, never passes through the gastrointestinal tract, and shows no clinically meaningful pharmacokinetic difference in renal impairment. That rules out the chelation, gastric-pH, enzyme-induction, and unchanged-renal-excretion mechanisms that drive most drug-nutrient depletion findings in this series.

Long-acting insulin analog · ATC A10AE05 · also sold as Levemir · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Insulin detemir in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: at least two independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named plausible mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: at least one Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit.
Yellow — Low
low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence to support even yellow, and no circulating claim exists to rebut as white. A disclosed absence of evidence (or, where noted, of accessible evidence this session), never reworded as reassurance.

What the research found

Potassium

Orange — Moderate

See study details

Insulin detemir shifts potassium from outside to inside cells, transiently lowering serum potassium and risking hypokalemia during dose initiation, correction of hyperglycemia, or use with other hypokalemia-risk drugs — a compartmental shift, not a whole-body deficit.

Full detail, limits and 1 references

What the grade means here: moderate: at least one Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null findings: No detemir-specific data were located showing clinically meaningful hypokalemia from routine, stable, once- or twice-daily subcutaneous basal dosing at steady state; the labeled and clinically documented magnitude of this effect is best established in acute, high-dose, or IV-insulin correction contexts.
  • At-risk subgroups: Concurrent diuretics, corticosteroids, or other hypokalemia-risk drugs; renal impairment; DKA/hyperosmolar-state correction; malnourished pediatric patients (Moulik 2012).

Regulatory status

FDA label for LEVEMIR (insulin detemir) states explicitly that "all insulins, including LEVEMIR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia," warning that untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death.

Population evidence

Tier A: drug-named pharmacodynamic warning in the regulatory label (this drug specifically). Supporting class-level context: a pediatric diabetic ketoacidosis (DKA) cohort study (Moulik et al. 2012, PMID 22610448) documented therapy-related hypokalemia as a recognized complication of insulin-based DKA correction, though this used IV regular insulin, not insulin detemir.

Mechanism

Named: insulin stimulates Na⁺/K⁺-ATPase, driving cellular potassium uptake. The same StatPearls entry on insulin notes IV insulin is used therapeutically to treat hyperkalemia via this mechanism.

Counter-evidence held on record

Insulin detemir is a basal-only analog not used for acute IV correction of DKA, so the larger, better-documented shift seen in DKA literature does not directly generalize to typical chronic subcutaneous basal dosing; the effect at steady-state basal dosing is mechanism-based and expected to be smaller, not separately quantified in a detemir-specific outpatient cohort. This is a transient intracellular shift, not a whole-body deficit. Routine potassium supplementation is not indicated for patients on stable basal insulin detemir; monitor serum potassium rather than pre-emptively supplementing, especially with impaired renal function or other hypokalemia-risk drugs.

Magnesium

Not graded — disclosed evidence gap

See study details

Mechanistically plausible (same intracellular-shift pathway documented for potassium) but no citable source was retrieved for insulin detemir, or for insulin generally, on magnesium status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: PubMed searches for "insulin detemir magnesium" returned only irrelevant drug-catalog listings; a broader search for insulin-therapy effects on hypomagnesemia in the DKA/refeeding context returned only tangential, potassium-focused results. No citable Tier B or C source specific to insulin (detemir or class) and magnesium was retrieved before this session's web-fetch channel became persistently rate-limited by the outbound research proxy. No confirmed circulating consumer claim was identified either, though this review's ability to audit consumer sources was itself constrained by an exhausted web-search budget.

Tooling note

Disclosed as a tooling-limited gap, not a confirmed absence of literature. The same Na⁺/K⁺-ATPase-driven shift mechanism documented for potassium is plausible for magnesium and should be re-checked with fuller access in a future revision.

Phosphate

Not graded — disclosed evidence gap

See study details

Mechanistically plausible via the same insulin-driven intracellular shift implicated for potassium (the classic mechanism behind hypophosphatemia in DKA correction and refeeding syndrome), but no citable insulin-detemir or general-insulin source was retrieved this session.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A search for "insulin therapy hypophosphatemia hypomagnesemia diabetic ketoacidosis" returned four results, all focused on DKA management broadly or on potassium specifically; none provided phosphate-specific data with insulin (of any type, including detemir) named as the studied exposure. No confirmed circulating consumer claim was identified for insulin and phosphate.

Tooling note

This review's web-fetch channel was persistently rate-limited throughout, and the web-search budget was already exhausted, which constrained the number of phrasings and hosts that could be tried for this category. Flagged for re-checking in a future revision.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

No evidence indicates insulin detemir harms mitochondrial structure or function; disease-state physiological literature instead links adequate insulin signaling to preserved or enhanced skeletal-muscle mitochondrial biogenesis, the opposite of a depletion signal.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding. Yellow

Limits on what this shows

  • Key negative/null findings: None identified for detemir specifically; the absence of drug-specific data is itself the main limitation of this entry.
  • At-risk subgroups: Not established for detemir. The disease-state literature concerns patients with insulin resistance or type 2 diabetes generally, the population insulin detemir is prescribed to treat, so confounding by indication is likely.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier C, class-level and physiological, not detemir-specific: human aging-muscle studies in which insulin plus amino acids enhanced muscle mitochondrial biogenesis; reviews linking insulin resistance (the disease state, not insulin therapy) to impaired mitochondrial bioenergetics, biogenesis, and dynamics. No study using insulin detemir itself was located.

Mechanism

Insulin receptor signaling supports mitochondrial biogenesis programs; this is normal physiological insulin action, present with any adequate insulin exposure, not a pharmacologic effect unique to detemir.

Counter-evidence held on record

The literature describing mitochondrial impairment concerns insulin resistance, the condition insulin treats, not insulin therapy causing harm; this is the opposite causal direction from a depletion claim (confounding by indication, Hard Rule 6). This is a reverse-direction, protective-leaning signal from physiological literature, not drug-specific evidence of benefit. It must never be marketed as insulin detemir "improving mitochondrial health"; it reflects normal insulin biology in disease-state research not designed to test this drug. Shares its underlying source with the ATP production entry below (see Overlap map).

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

A direct human comparison of insulin detemir against another insulin regimen on oxidative-stress markers exists, but this review could not confirm its quantitative outcome; the only detemir-specific animal data found show no signal distinct from another basal insulin.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding. Yellow

Limits on what this shows

  • Key negative/null findings: Murthy SN et al. (2012, Zucker fatty rats, balloon-injured carotid artery model) found phospho-eNOS expression elevated similarly with both NPH insulin and insulin detemir versus controls, with no significant difference between the two insulin types in other markers assessed (MnSOD, eNOS, NF-κB p65) — no detemir-specific oxidative-stress signal versus another basal insulin.
  • At-risk subgroups: Not established.

Regulatory status

Not addressed in the FDA label.

Population evidence

Naruse R, Takebayashi K, Morita K, Aso Y, Inukai T. "Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes." Endocr J. 2011;58(12):1055-63. PMID 21986033. Tier A by design (comparative clinical study, n=43, this drug in the cohort), but the results table could not be retrieved in this review (see access notes); only the design and cohort assignment were confirmed from a PubMed search-listing snippet, not the quantitative outcome or its direction.

Mechanism

Not named specifically for detemir. General insulin-signaling literature (Tier C, disease-state) associates improved glycemic control with reduced hyperglycemia-driven oxidative stress; this is a plausible but unconfirmed pathway.

Counter-evidence held on record

The Murthy 2012 animal data argue against a detemir-specific oxidative-stress effect distinct from NPH insulin. Do not present this as evidence that insulin detemir increases oxidative stress. The direction of the human comparative study could not be confirmed this session; this entry exists to flag that the comparison has been made, not to assert a result.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

Old animal and cross-sectional data hint at altered serum copper in insulin-treated diabetes, but no study isolates insulin therapy itself as the cause independent of the underlying diabetic state, and none used insulin detemir.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding. Yellow

Limits on what this shows

  • Key negative/null findings: None specifically located; the absence of a well-controlled treatment-effect study is itself the limiting finding.
  • At-risk subgroups: Not established.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier C: Halim AB et al. "Serum mineral changes in dithizone-induced diabetes before and after insulin treatment" (1977, animal model, pre/post generic insulin treatment, serum mineral panel). Isbir T et al. "Zinc, copper and magnesium status in insulin-dependent diabetes" (1994, cross-sectional, n=20 established type 1 diabetes patients; a disease-state snapshot, not a treatment-effect comparison). Neither used insulin detemir (unavailable before 2004) or isolated insulin's contribution from the diabetic disease state itself.

Mechanism

No direct mechanism is named for insulin affecting copper handling. Any signal in these old studies is more plausibly related to diabetes disease state (for example, altered ceruloplasmin or inflammatory copper handling in poorly controlled diabetes) than to an insulin-drug effect.

Counter-evidence held on record

Confounding by indication (Hard Rule 6) is not excluded in either source; both describe diabetic patients broadly, not an insulin-initiation-versus-no-insulin comparison, so any copper abnormality could reflect the underlying disease rather than the drug. Do not present as insulin detemir depleting or otherwise altering copper status. The underlying data are decades old, non-detemir, and confounded by diabetes disease state itself. Shares its evidence base with the Iron entry below (see Overlap map).

Iron

Yellow — Low

See study details

The same old animal model reporting altered serum minerals in chemically induced diabetes recorded elevated, not depleted, serum iron in untreated animals; no detemir-specific or well-controlled human treatment-effect study on iron status was located.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding. Yellow

Limits on what this shows

  • Key negative/null findings: None specific to iron beyond the single old animal source; no human insulin detemir cohort data were found.
  • At-risk subgroups: Not established.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier C: Halim AB et al. 1977 (animal, dithizone-induced diabetes, pre/post generic insulin treatment) reported serum zinc, iron, and potassium levels "higher than normal" in untreated diabetic animals per the accessible search-listing snippet; the post-treatment normalization direction could not be confirmed from the source text available in this review.

Mechanism

No direct mechanism is named for insulin affecting iron handling or absorption. Insulin detemir is not orally absorbed and has no described interaction with iron transporters (for example DMT1, ferroportin) or with hepcidin.

Counter-evidence held on record

Same confounding-by-indication limitation as copper (Hard Rule 6); a single, nearly 50-year-old, chemically induced animal model is not sufficient to establish a treatment-effect direction in humans on insulin detemir. This is the weakest tier of supporting evidence in this dossier. It does not support any iron-depletion or iron-excess claim for insulin detemir in humans and must not be presented as such. Shares its evidence base with the Copper entry above (see Overlap map).

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No evidence was found that insulin therapy itself (as opposed to the underlying diabetic disease state) changes gut microbiome composition or diversity.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A PubMed search for "insulin detemir gut microbiome" returned zero results. A broader search for "insulin therapy gut microbiota type 1 diabetes" returned disease-state dysbiosis studies and a fecal-microbiota-transplantation intervention trial, none of which isolated insulin therapy itself as the exposure changing microbiome composition. No Tier B or C treatment-effect evidence and no confirmed circulating consumer claim were found for insulin detemir specifically.

Tooling note

This appears to be a genuine literature gap as far as this review's available tooling could establish, though the consumer-claim side of this audit was limited by web-search budget exhaustion.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

No insulin detemir-specific ATP data exist; the same class-level insulin-signaling physiology cited for mitochondrial burden associates insulin action with glucose-fueled ATP-generating capacity, a reverse-direction signal rather than a depletion concern.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only, class extrapolation where at least one class member has real data but this drug does not, a context flag, or a reverse-direction/protective finding. Yellow

Limits on what this shows

  • Key negative/null findings: None found specific to detemir.
  • At-risk subgroups: Not established.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier C, same class-level physiological/disease-state literature as the mitochondrial burden entry: AMPK- and insulin-signaling reviews describing insulin's role in cellular glucose delivery and oxidative capacity. No insulin detemir-specific ATP measurement study was located.

Mechanism

Insulin promotes GLUT4-mediated glucose uptake into muscle and adipose tissue, providing substrate for mitochondrial ATP synthesis; well-established general physiology, not a detemir-specific pharmacologic effect.

Counter-evidence held on record

This is normal insulin physiology present with any adequate insulin exposure, endogenous or any analog; it says nothing unique about detemir versus other basal insulins. Never present as an "energy-boosting" claim specific to insulin detemir; the evidence is class-level human and animal physiology, not a drug-specific finding. See Overlap map: shares its underlying source with the mitochondrial burden entry above; do not count these as two independent confirmations.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No hemoglobin, hematocrit, red-cell mass, or arterial-oxygenation data specific to insulin detemir were located, and no plausible mechanism links this drug's pharmacology to erythropoiesis or oxygen delivery.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A PubMed search for "insulin detemir hemoglobin weight gain" returned abundant weight-gain data (see Monitoring panel) but no hemoglobin, hematocrit, or oxygen-delivery results among the studies displayed. No mechanism in insulin detemir's pharmacokinetic or pharmacodynamic profile (a subcutaneously injected, non-metabolized peptide hormone acting on insulin/IGF-1 receptors) plausibly links it to erythropoiesis or arterial oxygenation. No Tier B or C evidence and no confirmed circulating consumer claim were found.

Tooling note

Flagged as a combined tooling-and-literature gap; a more targeted search (for example "basal insulin analog hematocrit" or "insulin erythropoietin") is recommended in a revision with fuller access.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Chromium

    Where it comes from: Circulates broadly in consumer supplement and drug-nutrient-depletion content that groups all "diabetes medications" together, often extending chromium's own separately-debated role in insulin sensitivity into a claim that diabetes drugs, including insulin, deplete chromium.

    Why it fails: A targeted PubMed search combining insulin detemir with chromium and vitamin B12 returned zero results. Insulin detemir is delivered subcutaneously, bypasses the gastrointestinal tract entirely, is not hepatically metabolized by drug-metabolizing enzymes, and has no described chelation, gastric-pH, or transporter-competition mechanism; the mechanisms by which oral drugs are typically linked to trace-mineral depletion do not apply to this drug. No Tier B or C evidence for insulin as a class affecting chromium status was located in this review.

  • Vitamin B12

    Where it comes from: Vitamin B12 depletion is a well-documented effect of metformin, via disruption of calcium-dependent, intrinsic-factor-mediated ileal absorption. Consumer content frequently generalizes this to "diabetes medications" as a category, sweeping in insulin despite the mechanism being specific to metformin's oral, gut-active pharmacology.

    Why it fails: No PubMed evidence links insulin detemir, or insulin therapy generally, to vitamin B12 status (search returned zero results). Insulin detemir's subcutaneous, non-oral route provides no plausible mechanism for interfering with intrinsic-factor-mediated ileal B12 absorption, the documented mechanism for metformin's effect. This is a category-level conflation, not evidence specific to insulin.

All references used above
  1. DailyMed. LEVEMIR (insulin detemir) injection, solution. Structured Product Label. — A-S Medication Solutions, setid 82192527-99aa-4b53-8ce9-9173668d309c. Regulatory label, Tier A.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, code A10AE05, insulin detemir. — Regulatory classification reference.
  3. NCBI Bookshelf / StatPearls. Insulin (general pharmacology entry). — Tier B, established pharmacology reference; not detemir-specific.
  4. Naruse R, Takebayashi K, Morita K, Aso Y, Inukai T. Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes. Endocr J. 2011;58(12):1055-63. PMID 21986033. — Comparative clinical study, n=43. Tier A by design (this drug in the cohort).Partially inaccessible: the individual PMID page and Europe PMC returned empty or rate-limited content, and the journal's own site (jstage.jst.go.jp) blocked automated access via robots.txt. Design and cohort were confirmed via a PubMed search-listing snippet; the quantitative outcome and its direction were not confirmed in this review.
  5. Murthy SN, et al. Effects of insulin detemir on balloon catheter injured carotid artery in Zucker fatty rats. (2012, animal model.) — Tier B, animal study using insulin detemir directly. Cited from a PubMed search-listing snippet.Full PMID/citation not independently confirmed beyond the search-listing snippet in this review; treat as partially verified.
  6. Halim AB, et al. Serum mineral changes in dithizone-induced diabetes before and after insulin treatment. (1977, animal model.) — Tier C. Cited from a PubMed search-listing snippet.Cohort excluded this drug: insulin detemir did not exist in 1977 (approved 2004); generic/unspecified insulin only, in a chemically induced animal model.
  7. Isbir T, et al. Zinc, copper and magnesium status in insulin-dependent diabetes. (1994, cross-sectional, n=20.) — Tier C. Cited from a PubMed search-listing snippet.Cohort excluded this drug: describes established type 1 diabetes disease state generally, not an insulin-detemir or insulin-initiation treatment-effect comparison.
  8. Moulik NR, Jayashree M, Singhi S, Bhalla AK, Attri S. Nutritional status and complications in children with diabetic ketoacidosis. 2012. PMID 22610448. — Tier C for this drug. Cited from a PubMed search-listing snippet.Cohort excluded this drug: pediatric DKA cohort treated with regular/IV insulin, not insulin detemir, which is a basal-only analog not used for acute DKA correction.
  9. PubMed search listings (multiple queries), searched directly for this review. — Queries run: insulin detemir + hypokalemia; + magnesium; + oxidative stress; + vitamin D (inconclusive fetch, not a confirmed zero-result); + gut microbiome; + hemoglobin/weight gain; + vitamin B12/chromium; insulin therapy + gut microbiota type 1 diabetes; insulin therapy + serum copper/zinc diabetes; insulin therapy + hypophosphatemia/hypomagnesemia diabetic ketoacidosis; insulin signaling + mitochondrial biogenesis/ATP skeletal muscle; insulin detemir + mitochondria (blocked by a reCAPTCHA challenge page, not completed).